Organon & Co | OGN - Operating Profit


Organon & Co reported $323M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Celltrion KRW 19.31B 6.4B Jun/2026
Cspc Pharmaceutical CNY 206.26M 1.02B Dec/2025
Deva Holding AS TRY 964.87M 240.32M Sep/2023
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Divis Laboratories Ltd INR 11.29B 3.15B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Kangmei Pharma CNY -35.26M 24.32M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 400K Dec/2024
Medical Developments International AUD -36K 444K Dec/2025
Merck USD 840M 2.72B Jun/2026
Neuren Pharmaceuticals AUD 17.01M 11.56M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Organigram Holdings CAD -9.79M 10.33M Mar/2026
Organon & Co USD 323M 57M Jun/2026
Ovoca Bio EUR -173K 990K Dec/2025
Pharma Mar EUR -1.4M 2.03M Jun/2026
Qiagen NV USD 141.4M 24.77M Jun/2026
Sartorius EUR 179.8M 15.8M Sep/2026
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tilray USD -20.01M 9.34M Sep/2025
Zealand Pharma A/S -539M 168.05M Mar/2026